Every colorectal cancer diagnosis raises one critical question: Is this cancer hereditary?

Myriad Oncology

Each step. Every patient. Exactly what you need.

Every colorectal cancer diagnosis raises one critical question: Is this cancer hereditary?

One question at diagnosis.
One solution that informs care.
The MyRisk® Hereditary Cancer Test.

Is this cancer hereditary?

Genetic understanding of colorectal cancer (CRC) has evolved. It’s no longer just about Lynch syndrome and Familial Adenomatous Polyposis (FAP) — we now know that 24 genes are linked to CRC, and positive findings can change surgical planning, surveillance, and family care.1,2

For years, age, family history, and mismatch repair (MMR) deficiency status were the main reasons to order germline testing. Today, we know those triggers may fail to identify many patients who carry actionable risk. Delaying germline testing can jeopardize the window to inform index surgery and early survivorship planning.
That’s why guidelines now support germline testing for more CRC patients at diagnosis, moving beyond age or family history as the main triggers.1

Don’t wait for MSI/IHC results — order germline testing at diagnosis to help guide surgical planning, management, and family care.

The MyRisk Test provides the complete hereditary picture for CRC, analyzing

SPEAK WITH OUR TEAM ABOUT HOW THE MYRISK TEST CAN INFORM CARE FOR YOUR CRC PATIENTS

Get started with Myriad Oncology

Request more information about how Myriad’s Oncology solutions can benefit you/your patients.


Don't know your NPI? Click Here

By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.

Hidden Fields











Hidden test fields

Contact Information

Germline testing informs colorectal cancer care in ways tumor testing alone cannot.

Surgery decisions supported by timely, actionable results

Germline results directly influence immediate care decisions.

  • In select hereditary colorectal cancer syndromes—including Lynch syndrome, APC‑associated FAP, and biallelic MUTYH‑associated polyposis—germline findings may inform surgical decision‑making regarding the extent of resection and anastomotic approach, balancing recurrence risk with functional outcomes.
  • The American Society of Colon and Rectal Surgeons (ASCRS) emphasizes individualized surgical planning for hereditary CRC syndromes.6

The MyRisk Test is built for the clinical timeline of CRC care: results are typically delivered within 14 days — or as fast as 7 days with STAT priority option, enabling evidence-based operative planning.

ORDER A TEST

Beyond surgery: informing surveillance, long-term management & family risk

Germline results shape the entire continuum of CRC care:

  • Surveillance: Lynch syndrome, MUTYH-associated polyposis (MAP), or familial adenomatous polyposis (FAP) syndrome carriers typically need intensified surveillance with colonoscopy as often as annually to reduce the risk of an interval cancer, vs every 5 years for sporadic CRC cases1,7,8
  • Second primary cancer prevention: Hereditary CRC syndromes are often linked to an increased risk of secondary cancers. I.e. Lynch syndrome carriers face up to 50% risk of endometrial cancer, requiring early specialty referral.1
  • Family risk assessment: Positive results trigger cascade testing and inform preventive care strategies for relatives who test positive.1

The MyRisk Test is built for the clinical timeline of CRC care: results are typically delivered within 14 days — or as fast as 7 days with STAT priority option, enabling evidence-based operative planning.

ORDER A TEST

A complete solution beyond testing

The MyRisk Test goes beyond identifying hereditary colorectal cancer risk — it provides clinicians with a guideline-aligned, clinically actionable foundation for surgical planning, surveillance, long-term management, and patient support.

Full hereditary coverage

  • Analyzes all 24 CRC‑linked genes cited in national guidelines1-3
  • Excludes non‑guideline genes, avoiding uncertainty common in broader panels1-3
  • 63 guideline‑recommended genes across 11+ cancer types for broader hereditary insight1-3

Clear, timely, guideline-aligned results

  • Reports include guideline-aligned operative and surveillance recommendations
  • Results typically return within 14 days — or as few as 7 days with STAT priority, enabling genetic insight before surgery
  • Easy to share with patients and multidisciplinary teams

Industry-leading accuracy

  • Industry’s lowest reported VUS rates in BRCA1/2, giving you clearer answers for patient management9
  • Definitively classifies up to 63% of variants that other labs could not10

Patient education and comprehensive support

  • On‑demand pre‑ and post‑test patient education available from board‑certified genetic counselors.
  • Easy eligibility screening tools based on national guidelines
  • Most patients pay no out‑of‑pocket cost for the MyRisk Test11
  • Myriad helps navigate coverage

Request Information

Start your CRC patients’ care journey with the MyRisk Test: one solution that helps inform surgical planning, management, surveillance, and multidisciplinary care to help improve patient outcomes.

More resources

  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed March 9, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 
  2. Tung N, Ricker C, Messersmith H, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol. 2024;42(21):2599-2615.
  3. Internal product development data on file at Myriad Genetics, Inc. Last updated 2025.
  4. Yap TA, Ashok A, Stoll J, et al. Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines. JAMA Netw Open. 2022;5(5):e2213070.
  5. Yurgelun MB, Kulke MH, Fuchs CS, et al. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.J Clin Oncol. 2017;35(10):1086-1095. 
  6. Vogel JD, Felder SI, Bhama AR, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer. Dis Colon Rectum. 2022;65(2):148-177. 
  7. Herzig DO, Buie WD, Weiser MR, et al. Clinical Practice Guidelines for the Surgical Treatment of Patients With Lynch Syndrome. Dis Colon Rectum. 2017;60(2):137-143.
  8. Poylin VY, Shaffer VO, Felder SI, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Inherited Adenomatous Polyposis Syndromes. Dis Colon Rectum. 2024;67(2):213-227. 
  9. Mundt E, McGreevy K, Nix P, Cummings S. Myriad’s Multidisciplinary Approach and Consistent Investment in Variant Classification for Clinical Decision Making [White paper]. Myriad Genetics. 2025.
  10. Gradishar W, Johnson K, Brown K, et al. Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory. Oncologist. 2017;22(7):797-803.
  11. Data on File at Myriad Genetics, Inc. Based on a review of 12 months of past claim data for major insurance carriers across the US, the majority of patients face no out-of-pocket costs for their MyRisk test. Last updated 2024. 

©Myriad Genetics, Myriad Oncology, MyRisk, and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions.

Locations

United States
Europe
Japan